Immediate Impact
1 standout
Citing Papers
Present and future of cancer nano-immunotherapy: opportunities, obstacles and challenges
2025 Standout
Works of Yuko Tanabe being referenced
Safety and efficacy of nivolumab plus bevacizumab, paclitaxel for HER2-negative metastatic breast cancer: Primary results and biomarker data from a phase 2 trial (WJOG9917B)
2022
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Yuko Tanabe | 16 | 33 | 11 | 5 | 43 | ||
| Rebecca Kalikawe | 21 | 36 | 26 | 14 | 5 | 60 | |
| Spartak Valev | 18 | 45 | 8 | 9 | 6 | 66 | |
| Sarah Warren | 9 | 32 | 5 | 6 | 40 | ||
| Noah Theiss | 22 | 19 | 9 | 8 | 5 | 48 | |
| Karina Vianna | 19 | 36 | 3 | 7 | 6 | 39 | |
| Nicole Gianino | 21 | 32 | 16 | 5 | 47 | ||
| Marta Casarrubios | 9 | 27 | 3 | 15 | 5 | 42 | |
| Shusuke Kawashima | 7 | 29 | 3 | 21 | 6 | 54 | |
| Maartje G. Schouwenburg | 15 | 36 | 4 | 19 | 5 | 51 | |
| Sandra Re | 14 | 33 | 4 | 18 | 5 | 44 |
All Works
Loading papers...